Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/80547
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models |
Author: | Luo, K. Ko, C. Yue, G. Lee, M. Siu, W. Lee, J. Shum, W. Fung, K. Leung, P. Li, G. Evdokiou, A. Lau, C. |
Citation: | Cancer Letters, 2013; 339(1):42-48 |
Publisher: | Elsevier Sci Ireland Ltd |
Issue Date: | 2013 |
ISSN: | 0304-3835 1872-7980 |
Statement of Responsibility: | Ke-Wang Luo, Chun-Hay Ko, Grace G.L. Yue, Michelle Y.Y. Lee, Wing-Sum Siu, Julia K.M. Lee, Wai-Ting Shum, Kwok-Pui Fung, Ping-Chung Leung, Gang Li, Andreas Evdokiou, Clara B.S. Lau |
Abstract: | This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer. |
Keywords: | Zoledronic acid Metronomic Conventional Anti-osteolysis Metastasis |
Rights: | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
DOI: | 10.1016/j.canlet.2013.07.024 |
Published version: | http://dx.doi.org/10.1016/j.canlet.2013.07.024 |
Appears in Collections: | Aurora harvest 4 Orthopaedics and Trauma publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.